Scott M. Rocklage earned his bachelor’s degree in chemistry from the University of California, in Berkley. Scott has a Ph.D. in Chemistry from Institute of Technology of Massachusetts and currently operates from his office in Waltham. Rocklage has more than 20 years of experience in managing strategic leadership roles that have resulted in the approval of three new drug applications in the United States. The drugs approved by the FDA included Cubicin, Teslascan and Omniscan, and the initiation of approving six more drugs. Scott currently works as the managing partner of 5AM Ventures after his promotion from the venture partner position of the firm. Before joining 5AM Ventures, Scott was the chief executive officer and chairman of Nycomed Interventional and has served in various R & D positions at Catalytica and Salutar. He was also the executive director of Ilypsa, which was later acquired by Amgen and of Miikana, which is in current ownership of EntreMed. Scott is a board chairman of Achaogen Relypsa, Semprus, and Relypsa. He is a member of the Council of Pulmatrix, WaveRx, and Variation. Scott is an associate of WhiteHead Institute board.
5AM Ventures is a venture capital company that creates and develops biotechnological firms. In 2003, Scott joined 5AM’s team of investment professionals Andy Schwab, John Diekman and Carin Mueller. 5AM has biotechnology investments in Ambrx, Alexza, Clescia Therapeutics, Miikana, Kalypsys and Symyx Therapeutics. John Diekman, the founder and managing partner of 5AM, stated that Scott’s recruitment into the firm would add to the intellectual resources of the team. He noted that Scott’s experience in approving drugs, constructing pipelines for pharmaceutical companies was necessary for the advancement of 5AM. Scott commented that he was enthusiastic to join the team of accomplished investors and entrepreneurs. He stated that he was looking forward towards the growth of 5AM’s innovation and biotechnology.
Scott Rocklage has proven leadership skills which he used to raise 500 million dollars for one of his former employers. He helped Cubist Pharmaceuticals build a public offering and successfully led the financing of many other projects. Besides serving as the current venture partner of 5AM, he is also the director of Miikana Therapeutics and MDS Protemics Inc. In 2016, Scott Rocklage and his wife Patty Rocklage visited the Department of Chemistry of MIT to tour the newly constructed lab. The MIT team celebrated the professor’s financial contribution to the project of building the university’s new nanochemistry and nanotechnology labs. Scott carried out his academic research in the department of chemistry and won the 2005 Nobel Prize in Chemistry. When he received a request to contribute to the development of the new labs, he was enthusiastic to help. Scott is a co-inventor and inventor of more than 30 United States patents and has over 100 peer-analyzed publications.